Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma (Q79776928)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

title

Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

metastatic renal cell carcinoma

1 reference

Nizar Tannir

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Eric Jonasch

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Lance C Pagliaro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Paul Mathew

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Arlene Siefker-Radtke

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Laurence Rhines

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Patrick Lin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Rita Tibbs

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Kim-Anh Do

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Sue-Hwa Lin

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Shi-Ming Tu

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

1 August 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

page(s)

497-505

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

Osseous metastases secondary to renal cell carcinoma

25 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Bone metastases: pathophysiology and management policy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Mechanisms of bone metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Biochemical markers and skeletal metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Markers of bone resorption in patients treated with pamidronate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22038

7 January 2021

Identifiers

DOI

10.1002/CNCR.22038

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16795067%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference